← Back to Search

Arm 2 (HU Toolbox app) for Sickle Cell Disease

N/A
Waitlist Available
Led By Jane Hankins, MD
Research Sponsored by St. Jude Children's Research Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 9 months
Awards & highlights

Study Summary

This trial will test two innovative interventions utilizing mobile health to address both patients' and providers' needs in order to improve clinical provider prescribing of and patient adherence to hydroxyurea.

Eligible Conditions
  • Sickle Cell Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 9 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 9 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Mean Change in PDC From Baseline Through 24 Weeks
Secondary outcome measures
Change Bilirubin
Change in Absolute Neutrophil Percentage
Change in Fetal Hemoglobin
+15 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Arm 2 (HU Toolbox app)Experimental Treatment1 Intervention
Provider receives the HU Toolbox app for 9 months
Group II: Arm 1 (InCharge Health app)Experimental Treatment1 Intervention
Patient receives the InCharge Health app for 6 months
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
InCharge Health mobile application
2019
N/A
~390
HU Toolbox mobile application
2019
N/A
~390

Find a Location

Who is running the clinical trial?

University of MemphisOTHER
70 Previous Clinical Trials
11,507 Total Patients Enrolled
RTI InternationalOTHER
188 Previous Clinical Trials
875,582 Total Patients Enrolled
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,836 Previous Clinical Trials
47,850,475 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
JMIR Research ProtocolsJournal
Integration of Mobile Health into Sickle Cell Disease Care to Increase Hydroxyurea Utilization: Protocol for an Efficacy and Implementation Study
Hankins, Jane S, Nirmish Shah, Lisa DiMartino, Donald Brambilla, Maria E Fernandez, Robert W Gibson, Victor R Gordeuk, et al.. 2020. “Integration of Mobile Health into Sickle Cell Disease Care to Increase Hydroxyurea Utilization: Protocol for an Efficacy and Implementation Study”. JMIR Research Protocols. JMIR Publications Inc.. doi:10.2196/16319.
clinicaltrials.govStudy
Integration of mHEALTH Into the Care of Patients With Sickle Cell Disease to Increase Hydroxyurea Utilization
2019. "Integration of mHEALTH Into the Care of Patients With Sickle Cell Disease to Increase Hydroxyurea Utilization". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04080167.
~71 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top